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Summary Cisplatin is one of the most active cytotoxic agents in the treatment of testicular cancer, but its
clinical use is associated with side-effects such as ototoxicity, neurotoxicity and nephrotoxicity. Long-term
kidney damage from cisplatin particularly affects the proximal tubular apparatus and can be detected by
increased urinary excretion of brush-border enzymes, such as L-alanine-aminopeptidase (AAP), and
magnesium. In the current study, the flavonoid silibinin was used as a nephroprotectant for cisplatin-induced
nephropathy in a rat animal model. Infusion of silibinin before cisplatin results in a significant decrease in
glomerular (indicated by creatinine clearance and serum urea level) and tubular kidney toxicity (excretion of
brush-border enzymes and magnesium). Silibinin given alone had no effect on renal function. In order to
exclude an inhibition of the anti-tumour activity of cisplatin and 4-hydroperoxy-ifosfamide by co-
administration of silibinin, in vitro studies were performed in three established human testicular cancer cell
lines. Dose-response curves for cisplatin (3-30 000 nmol) combined with non-toxic silibinin doses
(7.25 x 10-6 or 7.25 x 10-5 mol 1-1) did not deviate significantly from those of cisplatin alone as measured
by relative cell survival during a 5 day assay using the sulphorhodamine-B staining technique. Also silibinin did
not influence the cytotoxic activity of 4-hydroperoxy-ifosfamide (30- 10 000 nmol) in vitro. In summary, these
in vitro data rule out a significant inhibition of the anti-tumour activity of the major nephrotoxic components,
cisplatin and 4-hydroperoxy-ifosfamide, by co-administration of silibinin in a human germ cell tumour cell line
model. Together with these demonstrated cytoprotection effects in the rat animal model, these data form the
basis for a randomised clinical trial of silibinin for the protection of cisplatin-associated nephrotoxicity in
patients with testicular cancer.
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With the introduction of cisplatin-based combination
chemotherapy, testicular cancer has become a highly curable
malignancy even in patients with metastatic disease (Williams
et al., 1987; Einhorn et al., 1977). Approximately 75-80% of
all patients can expect to be cured by standard combination
chemotherapy, such as PEB (cisplatin, etoposide and
bleomycin) or PEI (cisplatin, etoposide and ifosfamide).
Based on the advances achieved by the use of cisplatin-
based chemotherapy, interest has now also focused on
treatment-related toxicity. Cisplatin (DDP) represents one
of the most active cytotoxic agents in the treatment of
testicular cancer, but its clinical use is associated with
particular side-effects, such as ototoxicity, neurotoxicity and
nephrotoxicity (Bitran et al., 1982; Hacke et al., 1983;
Werner-Hansen et al., 1988; Schilsky et al., 1982). The risk
of DDP-associated nephrotoxicity has been reduced by the
use of hyperhydration and forced diuresis, but persistent
kidney damage is still found in some patients (Daugaard et
al., 1988a). The effects of DDP on renal function have been
extensively studied in animal models. In a rat model the type
of DDP nephrotoxicity seems similar to humans, affecting
different segments of the nephron, such as the tubular
apparatus and the glomerulus (Jones et al., 1985; Safirstein
et al., 1981). Impaired transport processes occur at the
luminal and to a lesser degree at the contra-luminal side of
the proximal tubular membrane and morphological examina-
tions have revealed necrotic cells in the proximal tubules
(Ammer et al., 1993; Field et al., 1989). The mechanisms of
DDP nephrotoxicity are still not fully understood. However,
the generation of free oxygen radicals in tubular cells has
been proposed as an important pathogenic process (Ishikawa
et al., 1990; Hannemann et al., 1988). Further evidence points
to the inhibition of protein synthesis in tubular cells by DDP
(Tay et al., 1988).
The management of nephrotoxicity requires either that
Correspondence: C Bokemeyer
Received 22 April 1996; revised 1 July 1996; accepted 8 July 1996
DDP is discontinued or that doses are reduced. However, this
may result in inferior anti-tumour activity. Cytoprotective
agents have been developed to ameliorate a variety of
functional disorders (Munshi et al., 1992; Anderson et al.,
1990). Silibinin (Figure 1) is one of three isomers constituting
silymarin, a flavonoid extracted from Sylibum marianum, the
milk thistle, that has long been known as a medicinal plant
(Wagner et al., 1974; Hahn and Mayer, 1981). Silibinin has
been successfully used as a protective agent in clinical and in
experimental work in in vivo and in vitro models ofliver toxicity
(Valenzuela and Guerra, 1985; Valenzuela et al., 1985).
Silibinin possesses membrane-stabilising, anti-inflammatory,
antioxidant and RNA and protein synthesis-stimulating
properties (Faulstich et al., 1980; Middleton et al., 1992;
Sonnenbichler and Zetl, 1987; Mira et al., 1994). However,
before the clinical use of new cytoprotective agents, not only
protection from toxicity, but also the absence ofan interference
of the agent with the anti-tumour activity of the cytotoxic
agents used, have to be demonstrated (Bokemeyer et al., 1994).
The first aim of the preclinical study presented here was to
evaluate in vivo the protective effects of the flavonoid silibinin
on acute DDP nephrotoxicity in an established rat
nephrotoxicity model. Serum and urinary parameters
specifically detecting glomerular and tubular damage were
therefore studied following treatment with DDP and/or
silibinin. The second aim was then to evaluate in vitro, in
three human non-seminomatous germ cell tumour cell lines,
whether silibinin interferes with the cytotoxicity of DDP and
also ifosfamide, which in many standard combination
chemotherapies is applied together with DDP.
Materials and methods
In vivo studies on a rat model of DDP nephrotoxicity
Female Wistar rats with an initial body weight between 170
and 230 g were used. Animals, housed 3-4 per cage under
standardised laboratory conditions with controlled light-Silibinin for prevention of cisplatin nephrotoxicity
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dark cycle, room temperature (21 C) and moisture, had free
access to tap water and pellet diet (Altromin R, Lage,
Germany).
Treatment of animals A total of 45 rats were randomised
into four groups. One group received cisplatin (DDP)
(n = 12), one group silibinin and DDP (n = 11), one group
silibinin alone (n =10) and one group the vehicle isotonic
saline (n = 12). The animals only received one injection of the
compounds.
DDP (Medac, Hamburg, Germany) dissolved in saline was
given at a concentration of 5 mg kg-' body weight (b.w.).
Silibinin (C25H22O1, FW 482.45) was given as silibinin-C-2,3-
dihydrogen-succinate, disodium salt (MADAUS AG, Co-
logne, Germany). The compound was dissolved in saline, the
animals received about 0.4 mmol silibinin kg-' body weight
(=0.2 g silibinin kg-1 b.w). This dose is below the oral
maximum tolerated dose (MTD) that was > 1000 mg kg-'
body weight (U Mengs, MADAUS AG, Cologne, personal
communication). In the group with combined treatment
silibinin was given 1 h before the injection of DDP: studies
on humans had shown an elimination half-life of 6.3 h
(Lorenz et al., 1984). All injections were given i.v. into the
tail vein.
Sample collection Urine and plasma samples for an
assessment of kidney function were collected during a
control phase before treatment (day -1) and on days 1, 3
and 7 following treatment. For sample collection, animals
were housed in individual metabolic cages, which allowed
collection of urine samples without food or faecal contam-
ination. Urine was collected overnight under paraffin oil to
avoid evaporation. After each collection, a venous blood
sample was drawn from the orbital plexus under light ether
anaesthesia. Urine samples were supplemented with 0.01%
sodium nitrite. Urine and serum aliquots were stored at
-200C.
Analysis of urine andplasma samples For all animals, body
weight was recorded every 2 days and 24 h urinary volume
and total urinary protein were assessed as general parameters
of renal function. Total protein was measured with the
Coomassie blue binding method (Bradford, 1976). Changes in
urinary L-alanine-aminopeptidase (AAP) activity and urinary
magnesium were followed and served as parameters of kidney
tubular function. L-alanine-aminopeptidase (AAP, EC 3.4.11)
was measured by kinetic determination at 250C, pH 7.6, using
L-alanine-4-nitro-anilidehydrochloride as a substrate (Mat-
tenheimer et al., 1992). Magnesium was determined with the
xylidil blue method (Magnesium test kit, Merck, Darmstadt,
Germany). Serum and urinary creatinine were measured
using a Beckman creatinine analyser and reagents supplied by
the manufacturer (Creatinine analyser 2 Reagents, Beckman,
Munich, Germany) and served as kidney glomerular function
parameters. Blood urea and nitrogen levels were measured
with a test kit (Harnstoff Test-Kit, Boehringer, Mannheim,
Germany).
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Figure 1 Chemical structure of silibinin.
Calculations and statistics Data are expressed as
mean+standard deviation (s.d.). Excretion rates were related
to body weight. Changes in excretion rates or serum levels of
analytes following treatment were assessed with ANOVA
procedures. Differences between groups on specific days were
evaluated with the t-test for independent data. The level of
significance was defined as P<0.01. Statistical analysis was
performed with SPSS 4.1 (SPSS, Chicago, IL, USA).
In vitro cytotoxicity studies on germ cell cancer cell lines
Drugs DDP was obtained from Medac (Hamburg, Ger-
many). A prodrug of the active metabolite of ifosfamide (4-
hydroperoxyifosfamide) was kindly supplied by ASTA
Medica AG (Frankfurt, Germany), since tumour cells
cannot metabolise ifosfamide. The product spontaneously
gives rise to the active in vivo metabolite (4-OH-Ifo) in
solution, which then further degrades to active derivatives.
Stock solutions were therefore prepared immediately before
use. The solid powder was stored at -20 °C and 8 mg
weighed out on the day of the experiment and dissolved in
phosphate-buffered saline (PBS) (approximate pH 7) to a
final concentration of 2 mg ml-1 (6.82 mM). Stock solutions
of silibinin (MADAUS AG, Cologne) were freshly prepared
for each experiment by dissolving 10 mg powder per ml of
culture medium and filter sterilising. Silibinin was used at
final concentrations from 3.62 x 10-7 to 3.62 x 10-3 mol 1-'.
Non-seminomatous germ cell cancer cell lines Three human
testicular germ cell tumour cell lines were used for the in vitro
experiments. The origin and histology of the initial tumour
and of the heterotransplantated nude mice tumour is shown
in Table I (Casper et al., 1987). The cell lines were grown as
continuous monolayer cultures in RPMI-1640 medium
supplemented with 10% fetal calf serum (FCS) (Biochrom,
Berlin, Germany), penicillin 2 IU ml-1, streptomycin
2 jMg ml-' and L-glutamine 0.04 mmol 1-'. For the experi-
ments, cells from passages 70 to 80 of the three cell lines were
used.
Treatment ofcell lines Initially, all cell lines were exposed to
silibinin at concentrations ranging from 3.62 x 10-7 Up to
3.62 x 10-3 mol 1-'; nine different concentrations of silibinin
were tested and each experiment was performed twice. The
rationale for the silibinin concentrations used was based on
the experience in animals. Most of the silibinin is excreted via
the bile, only a small percentage via the kidney. Pharmaco-
kinetic studies on animals showed a first-pass effect (Biilles et
al., 1975), therefore silibinin blood levels following oral
administration remain low. In the in vivo studies each animal
(body weight 200 g) received about 0.08 mM silibinin.
The initial plasma concentrations must have been
<0.01 mM ml-' (= 1 x 10-5 M 1 ). The concentrations
tested in the cell cultures were chosen based on this
calculation.
DDP was used at concentrations ranging from 3 to
30 000 nmol either applied alone or in combination with
0.05 mg ml-' or 0.005 mg ml-1 of silibinin. Measurements
were calculated as means with standard deviation from three
Table I Characteristics of three human testicular cancer cell lines
giving the histology of the primary tumour and histology of
xenografted nude mouse tumours
Histology of the Histology of the
Cell line patient tumour nude mouse tumour
H12.1 S,T,CC,EC EC,STGC,T
577LM TC, YS EC,T
1777NR CI-A TC -
TC, teratocarcinoma; YS, yolk sac tumour; T, teratoma; EC,
embryonal carcinoma; CC, choriocarcinoma; S, seminoma; STGC,
syncitiotrophoblastic giant cells.Silibinin for prevention of cisplatin nephrotoxicity
C Bokemeyer et al
2038
separate experiments. 4-Hydroperoxy-ifosfamide was tested
in cell lines 1777 NR-CLA and H 12.1 using a concentration
range from 30 to 10 000 nmol. 4-Hydroperoxy-ifosfamide
was given either alone or in combination with 7.25 x 10'6,
7.25 x 10-5 and 3 x 10-4 mol l-1 of silibinin.
Cytotoxicity assay To assess the cytotoxic effect of DDP and
ifosfamide either alone or in combination with silibinin, a
sulphorhodamine-B assay was used as described by Skeehan et
al. (1990). In brief, cells were seeded into 96-well microtitre
plates at cell densities previously determined to give
exponential growth during the period of the experiment. Cell
survival relative to non-treated controls was then quantified
on day 5 after 96 h of drug exposure. Medium was carefully
removed and the cells were fixed with 100 ktl of 10%
trichloroacetic acid overnight. After washing, the plates were
stained with 0.4% sulphorhodamine-B in 1% acetic acid for
30 min and, after additional washing and drying, the dye was
solubilised in 100 1l TRIS-base (10 mmol, pH 8.5). The
absorbance was read in an automatic plate reader at a
wavelength of 570 nm. Eight separate wells were used for one
drug concentration and all experiments were performed in
triplicate. The concentration that inhibited tumour cell growth
by 50% (IC50) was obtained graphically from semi-logarithmic
dose-response plots.
Results
In vivo studies on a rat model of DDP nephrotoxicity
Cisplatin led to a decline in kidney function. Silibinin
administered alone did not affect any of the investigated
parameters of renal function (data not shown).
Animals treated with DDP alone showed a significant
reduction in creatinine clearance, which was most pro-
nounced on day 3 following treatment. This indicates
glomerular damage. No such changes could be observed in
the group treated with silibinin and DDP (Table II). Plasma
levels of urea were concomitantly elevated in the group given
DDP, but not in the group that was pretreated with silibinin
(Figure 2).
Tubular function was affected by DDP treatment,
indicated by a significant increase in the excretion of AAP.
This increase was significantly less pronounced in animals
pretreated with silibinin (Figure 3). Mean fractional
magnesium excretion ranged from 10 -15% of the filtered
magnesium load in the animal group studied during the
control phase (day - 1). Following cisplatin, an approxi-
mately 2.5-fold increase in magnesium excretion was seen,
resulting in reduced serum magnesium levels at day 7 in
animals receiving DDP alone (0.82+0.05 mmol 1` on day
-1, 0.62+0.13 mmoll-' on day 7, P<0.01, t-test). No
significant alteration of urinary magnesium excretion and of
magnesium serum levels were found when DDP was given
after pretreatment with silibinin.
In vitro cytotoxic activity assays on germ cell cancer cell lines
Silibinin cytotoxicity Figure 4 shows the dose response
curves of the cell lines to silibinin alone. The response of
Table II Changes in creatinine following administration of DDP
and/or silibinin in a rat animal model of DDP nephrotoxicity
Creatinine clearance in mlmin-m
x JOOg body weight-]
Group Day -1 Day 3 Day 7
Sodium chloride 0.47+0.03 0.49+0.06 0.51 +0.05
Silibinin 0.59 +0.08 0.51 +0.08 0.53 +0.09
DDP 0.54+0.09 0.15+0.04* 0.42+0.06*
Silibinin + DDP 0.32+0.06 0.38+0.09 0.44+0.08
*P<0.01 against control phase (day -1), ANOVA.
the cell lines was rather variable, but the IC50 of silibinin in
the cell lines investigated was approximately 1.45 x 10-4
mol 1` for cell line 577LM and > 1.45 x 10' mol 1- for
the other two cell lines. Two relatively non-cytotoxic
concentrations of silibinin (7.25 x 10'6 and
7.25 x 0 -mol -1) and two relatively toxic concentrations
(1.45 x 10-4 and 7.25 x 10-' mol 1 ') were therefore chosen
for further studies with the combination of either DDP or
ifosfamide, over a 9-fold log concentration.
Dose-response of cell lines to cisplatin with or without
silibinin The dose-response curves to DDP combined with
non-toxic silibinin doses (see above) did not deviate
significantly (tested with ANOVA procedures and t-test for
IC50 values) from those of DDP alone in any of the three cell
lines tested in vitro, indicating that silibinin at these
concentrations, has no effect on the cytotoxicity of DDP.
As an example, data for cell line 1777 NR CL-A are shown
in Figure 5.
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Figure 2 Changes in urea plasma levels in female Wistar rats
treated with cisplatin (DDP), silibinin and DDP, silibinin or
sodium chloride before treatment (day - 1) and on days 3 and 7
following treatment. (*P< 0.01 against day -1 of this group; for
dosage of drugs see Materials and methods section).
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Figure 3 Changes in the urinary activity of AAP in animals
treated with DDP (n = 12), silibinin and DDP (n=I1), silibinin
(n=10) or sodium chloride (n = 12) before treatment (day - 1)
and on days 3 and 7 following treatment. (*P<0.01 against day
-1 of this group, ANOVA; +P<0.01 between corresponding
days of the group given DDP or silibinin and DDP, t-test). For
dosage of drugs see Materials and methods section.
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Figure 4 In vitro dose response curves of three human testicular
germ cell cancer cell lines to different concentrations of silibinin
after 96h of drug exposure. 0, 577 LM; +, 1777 NR-CL-A; *,
H 12.1.
The combined dose - response curves to DDP for cell line
1777 NRCL-A in the presence of 1.45 x 10-4 or
7.25 x 10-4 mol 1-' silibinin were also not significantly
different from those of DDP alone. However, a slightly
antagonistic interaction between DDP and silibinin at higher
doses (7.25 x 10-4 mol 1-') was observed. The highest end of
the concentration range of cisplatin studied (10 imol), where
antagonism appears to be strongest, represents the peak
plasma concentration expected following an intravenous dose
of DDP of 100 mg m-2. The in vivo relevance of silibinin
concentrations of 7.25 x 10-4 mol l-1 is not known and,
therefore, the potential clinical implications are difficult to
assess. For cell lines 577 LM and H 12.1, no effect of silibinin
on DDP cytotoxicity was observed. Evaluation of the effect
of 7.25 x 10-4 mol l-1 silibinin on DDP cytotoxicity was not
reliable for these two cell lines, since silibinin alone at this
concentration gave only 40% relative cell survival.
In vitro cytotoxicity of 4-hydroperoxy-ifosfamide with or
without silibinin Data obtained from four independent
experiments consistently showed no influence of silibinin
on 4-hydroperoxy-ifosfamide cytotoxicity at any concentra-
tion studied in the cell lines 1777 NRCL-A and H 12.1. No
differences were observed between hypothetically calculated
concentrations of silibinin and 4-hydroperoxy-ifosfamide
when compared with the achieved dose - response curve for
the combination of both agents. Data for H 12.1 are shown
in Figure 6; data for 1777 NR CL-A are not given
separately.
Discussion
The nephrotoxicity of cisplatin (DDP) has already been
recognised during early phase I trials and Hayes et al. (1977)
were able to demonstrate that the renal toxicity of high-dose
bolus cisplatin (> 100 mg m-2) could be ameliorated by
forced diuresis and hydration (Higby et al., 1974). In order to
use DDP in germ cell cancer patients in combination
chemotherapy regimens without severe nephrotoxicity, the
dose of DDP is usually split to 20 mg m-2x 5 days. This
schedule has been incorporated into the formerly used
regimen of platin, vinblastine and bleomycin (PVB) and
into the current standard PEB regimen (Einhorn et al., 1977;
Williams et al., 1987). Since the nephrotoxicity of DDP seems
to be related to peak serum-free platinum levels, DDP bolus
doses >100 mg m-2 would be predicted to be more toxic
than smaller daily doses such as 20 mg m-2 x 5 days (Reece
et al., 1987). On the other hand, reducing DDP to cumulative
doses lower than 75 mg m-2 at 3 week intervals results in
inferior survival in patients with metastatic germ cell cancer
(Samson et al., 1984). Thus, adequate platinum dosing
appears to be relevant for maintaining cure rates but may
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Figure 5 In vitro dose-response curve of cell line 1777 NR CL-
A to DDP alone (0) and DDP in combination with 7.25 x 10-5
(a) or 7.25 x 10-6 (A) moll - of silibinin.
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Figure 6 In vitro dose-response curve of cell line H 12.1 to 4-
hydroperoxy-ifosfamide alone (0) and in combination with
7.25x 10-6moll M (I) 7.25x 10-5mol-1 (*), 1.45x 10-4
molI-l (l) or 2.9 x10-4mo1 silibinin.
also be associated with a higher incidence of acute and late
nephrotoxicity (Osanto et al., 1992). Vigorous hydration
using at least 3 1 of normal saline per 24 h before and during
cisplatin application, in combination with forced diureses by
mannitol or furoseamide are standard precautions taken to
prevent DDP nephrotoxicity.
Cytoprotective agents, particularly sulphydryl-containing
drugs, have been investigated as cytoprotectants against
nephrotoxicity (Anderson et al., 1990). The current study
shows that the flavonoid agent silibinin has a protective effect
on renal function. Creatinine clearance and plasma levels of
urea were taken as indicators of glomerular function and
excretion of a brush-border enzyme and magnesium as
indicators of tubular damage.
The changes in renal function observed in the rat model as
described above correlate well with the nephrotoxic effects of
DDP observed in man (Daugaard et al., 1988b). Alterations
in creatinine clearance and urea serum levels observed
following treatment with DDP, but not following treatment
with silibinin and DDP (Table II, Figure 1), are taken as
indications of an altered glomerular function. Creatinine is
filtered in the glomerulus, but tubular backleak of creatinine,
following, for example, tubular obstruction, can also occur.
However, backleak does not play a role in this early stage of
nephropathy in the animal model studied (Jones et al., 1985).
Excretion of the tubular enzyme alanine-aminopeptidase
(AAP) served as an indicator of proximal tubular function
(Pfleiderer et al., 1980; Fels et al., 1994). Urinary activity of
this brush-border enzyme was significantly elevated following
treatment of Wistar rats with DDP. This increase was
significantly less pronounced in animals that had received
silibinin before DDP (Figure 2).
The aetiology of cisplatin nephrotoxicity is still not
completely solved. It has been demonstrated that the final
common pathway for DDP nephrotoxicity is damage to the
proximal tubular epithelial cell, resulting in magnesium-
wasting nephropathy (Mavichak et al., 1985; Schilsky et al.,
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1982). However, further tubular functions seem also to be
affected (Daugaard et al., 1988a). A functional study, such
as the one presented here, can only give limited information
on the mechanisms of DDP kidney damage or protection.
The involvement of free radicals in DDP nephrotoxicity has
been discussed (Ishikawa et al., 1990; Sadzuka et al., 1992).
Silibinin possesses antioxidant and membrane-stabilising
properties that have already been evaluated in hepatocytes
challenged with a variety of radical-generating drugs
(Valenzuela and Guerra, 1985; Valenzuela et al., 1985;
Soose, 1994). Another mechanism of renal toxicity of DDP
may be the depression of DNA, RNA and protein synthesis
as demonstrated in studies, in vitro (Tay et al., 1988).
Silibinin is known to up-regulate the function of a DNA-
dependent RNA polymerase I in liver cells (Sonnenbichler et
al., 1976; Sonnenbichler and Zetl, 1987) and may thereby
counteract the decrease in synthetic activity of the kidney.
Thus, the therapeutic activities of silibinin are based on a
variety of potentially protective effects. The phenolic
structure, for example, makes silibinin a radical scavenger,
although it also has membrane-stabilising and regenerative
properties (Faulstich et al., 1980; Ferenci et al., 1989;
Sonnenbichler and Zetl, 1986). It is currently difficult to
assess which of the properties of the flavonoid are
responsible for the protection observed in this study.
However, the number of potential mechanisms of action
may make silibinin advantageous compared with intracel-
lular radical scavengers, such as sodium thiosulphate.
The in vivo studies showed that silibinin at least partly
counteracts the nephrotoxic side-effects of DDP. In in vitro
studies on human cancer cell lines, it could then be shown
that the application of silibinin does not decrease the anti-
tumour activity of either DDP or ifosfamide. Although some
cell line-specific differences may exist, the available in vitro
data do not indicate a significant interaction of clinically
relevant levels of silibinin and the cytotoxic activity of these
two major drugs used in testicular cancer. Based on
pharmacokinetic studies in patients receiving oral silibinin,
the therapeutic plasma levels have reached a maximum of
7.25 x 10' mol I-', a range that has been tested in our
experiments (Lorenz et al., 1984). These levels did not
interfere with the anti-tumour activity of cisplatin in vitro.
However, adverse pharmacokinetic interactions in vivo had
not been addressed in our experiments. Since many attempts
to reduce DDP toxicity, e.g. the substitution of DDP by the
less nephrotoxic compound carboplatin, have resulted in
inferior clinical anti-tumour activity in non-seminomatous
germ cell cancer patients, cisplatin still remains the most
important drug in the treatment ofthis disease (Bajorin et al.,
1993). The current data support silibinin as a potentially
useful selective cytoprotective agent, which may prevent
nephrotoxicity without decreasing cisplatin or ifosfamide
anti-tumour activity. Since certain acute renal tubular
alterations, such as the elevated excretion of tubular brush-
border enzymes, recognised in testicular cancer patients
treated with DDP may also be ameliorated by the
application of silibinin, it might be speculated that long-
term kidney side-effects may also be avoidable. The current
data form the basis for a clinical study using cisplatin-based
combination chemotherapy including silibinin, in patients
with testicular cancer in order to reduce the acute and long-
term nephrotoxic potential ofcisplatin. A randomised clinical
study on kidney function in patients treated for testicular
cancer has been initiated.
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